0
ARTICLE |

Evaluation of an Interferon Inducer in Viral Respiratory Disease

David A. Hill, MD; Samuel Baron, MD; John C. Perkins, MD; Michael Worthington, MD; John E. Van Kirk, MD; John Mills, MD; Albert Z. Kapikian, MD; Robert M. Chanock, MD
JAMA. 1972;219(9):1179-1184. doi:10.1001/jama.1972.03190350025006.
Text Size: A A A
Published online

To evaluate the effect of an interferon inducer on respiratory tract virus infection, poly l.poly C was administered intranasally to volunteers for a seven-day period beginning one day prior to inoculation of rhinovirus 13 or type A2 influenza virus/Hong Kong/68. In three separate trials, toxic effects were not detected and there was a small, but definite, reduction in symptoms of upper-respiratory tract illness associated with drug treatment. However, there was a variable effect on the pattern of virus infection. In only one of the two rhinovirus studies was a reduction of virus shedding observed. Treatment did not decrease the shedding of type A2 influenza virus. The minimal amounts of nasal interferon stimulated by the intranasally administered poly l.poly C may have been responsible for the less-than-optimal results obtained.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs